Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Daratumumab (CD38 Antagonist) in Patients with Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer

NCT03473730 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03473730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03473730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Daratumumab (CD38 Antagonist) in Patients with Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
May 29, 2018
Completion date
January 27, 2025
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, clear cell renal cell carcinoma, malignant urinary system neoplasm, metastatic kidney carcinoma, stage iv renal cell cancer ajcc v8